Controlling the evolution of resistance

Journal of Process Control

Volumn 21, Issue 3, 2011, Pages 367-378

  Luo, Rutao ^a   Cannon, Lamont ^a   Hernandez, Jason ^a   Piovoso, Michael J ^b   Zurakowski, Ryan ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Combination Chemotherapy; Evolution; HIV; Optimal Control

Indexed keywords

BACTERIAL INFECTIONS; CANCER THERAPY; CHEMOTHERAPEUTIC AGENTS; COMBINATION CHEMOTHERAPY; DISEASE PROGRESSION; DRIVING FORCES; DRUG RESISTANCE; DYNAMIC BEHAVIORS; EFFECTIVE THERAPY; EVOLUTION; EVOLUTION MODELS; HIV; IN-VITRO; LABORATORY WORK; MATHEMATICAL METHOD; MATHEMATICAL MODELING; MODEL BASED APPROACH; NEW MATHEMATICAL MODEL; OPTIMAL CONTROLS; PANCREATIC CANCERS; SELECTION MODEL; SEQUENTIAL TREATMENTS; STEADY-STATE ANALYSIS; SUSCEPTIBILITY GENES; TREATMENT PHASE; TREATMENT PROCESS;

CHEMOTHERAPY; CONTROL; DISEASE CONTROL; DISEASES; GENETIC ENGINEERING; MATHEMATICAL MODELS; MEDICAL PROBLEMS; OPTIMIZATION;

GENE THERAPY;

EID: 79952575198     PISSN: 09591524     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprocont.2010.11.010     Document Type: Article

References (59)

1. R. Alvarez, and D. Curiel A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients Hum. Gene Ther. 8 5 1997 597 613 (Pubitemid 27202051)
2. S. Bonhoeffer, and M.A. Nowak Pre-existence and emergence of drug resistance in HIV-1 infection Proc Biol Sci 264 1382 1997 631 637 (Pubitemid 27241346)
3. G. Chang, S. Xu, M. Watanabe, H. Jayakar, M. Whitt, and J. Gingrich Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer J. Urol. 183 4 2010 1611 1618
4. R. Colgrove, and A. Japour A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance Antiviral Res. 41 1 1999 45 56 (Pubitemid 29132817)
5. R. D'Amato, R. D'Aquila, and L. Wein Management of antiretroviral therapy for HIV infection: modelling when to change therapy Antivir. Ther. (Lond.) 3 3 1998 147 158 (Pubitemid 28499632)
6. F. Doyle, L. Jovanovic, D. Seborg, R. Parker, B. Bequette, A. Jeffrey, X. Xia, I. Craig, and T. McAvoy A tutorial on biomedical process control J Proc. Cont. 17 2007 571 594
7. D. Finzi, M. Hermankova, T. Pierson, L. Carruth, C. Buck, R. Chaisson, T. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. Ho, D. Richman, and R. Siliciano Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 5341 1997 1295 1300 (Pubitemid 27495742)
8. C. Fletcher, P. Anderson, T. Kakuda, T. Schacker, K. Henry, C. Gross, and R. Brundage Concentration-controlled compared with conventional antiretroviral therapy for HIV infection AIDS 16 4 2002 551 560 (Pubitemid 34218850)
9. Y. Fujita, T. Nakamura, T. Aomori, H. Nishiba, H. Shinozaki, T. Yanagawa, K. Takagishi, H. Watanabe, Y. Okada, K. Nakamura, R. Horiuchi, and K. Yamamoto Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma J. Chemother. 22 3 2010 186 190
10. D. Ho, A. Neumann, A. Perelson, W. Chen, J. Leonard, and M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 6510 1995 123 126
11. D. Ishida, A. Nawa, T. Tanino, F. Goshima, C. Luo, M. Iwaki, H. Kajiyama, K. Shibata, E. Yamamoto, K. Ino, T. Tsurumi, Y. Nishiyama, and F. Kikkawa Enhanced cytotoxicity with a novel system combining the paclitaxel-2′- ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus. HF10 as a helper virus Cancer Lett. 288 1 2010 17 27
12. H. Jiang, S. Deeks, D. Kuritzkes, M. Lallament, D. Katzenstein, M. Albrecht, and V. DeGruttola Assessing resistance costs of antiretroviral therapies via measures of future drug options J. Infect. Dis. 188 2003 1001 1008 (Pubitemid 37268250)
13. S. Khalili, and A. Armaou An extracellular stochastic model of early HIV infection and the formulation of optimal treatment policy Chem. Eng. Sci. 63 17 2008 4361 4372
14. C. Kloft, J. Wallin, A. Henningsson, E. Chatelut, and M. Karlsson Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs Clin. Cancer Res. 12 18 2006 5481 5490 (Pubitemid 44497264)
15. N. Komarova, and D. Wodarz ODE models for oncolytic virus dynamics J. Theor. Biol. 263 2010 530 543
16. N. Komarova, and D. Wodarz Drug resistance in cancer: principles of emergence and prevention Proc. Natl. Acad. Sci. U.S.A. 102 27 2005 9714 9719 (Pubitemid 40981746)
17. B. Korber, K. Kunstman, B. Patterson, M. Furtado, M. McEvilly, R. Levy, and S. Wolinsky Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences J. Virol. 68 11 1994 7467 7481
18. I. Kuhn, P. Harden, M. Bauzon, C. Chartier, J. Nye, S. Thorne, T. Reid, S. Ni, A. Lieber, K. Fisher, L. Seymour, G. Rubanyi, R. Harkins, and T. Hermiston Directed evolution generates a novel oncolytic virus for the treatment of colon cancer PLoS ONE 3 6 2008 e2409
19. R. Kurdow, B. Schniewind, A. Boehle, S. Haye, L. Boenicke, P. Dohrmann, and H. Kalthoff Resistance developing after long-term ganciclovir prodrug treatment in a preclinical model of NSCLC Anticancer Res. 24 2B 2004 827 831 (Pubitemid 38625029)
20. C. Luna, and I.B. Navarro Management of methicillin-resistant staphylococcus aureus pneumonia Curr. Opin. Infect. Dis. 23 2 2010 178 184
21. R. Luo, M. Piovoso, and R. Zurakowski A generalized multi-strain model of HIV evolution with implications for drug-resistance management Proc. Am. Control Conf. 2009 2295 2300
22. R. Luo, M. Piovoso, and R. Zurakowski Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching Proc. Am. Control Conf. 2010 5155 5160
23. R. Luo, and R. Zurakowski A new strategy to decrease risk of resistance emerging during therapy switching in HIV treatment Proc. Am. Control Conf. 2008 2112 2117
24. L. Mansky Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line AIDS Res. Hum. Retrovir. 12 4 1996 307 314 (Pubitemid 26072304)
25. J. Martinez-Cajas, and M. Wainberg Antiretroviral therapy: optimal sequencing of therapy to avoid resistance Drugs 68 1 2008 43 72 (Pubitemid 350275684)
26. J. Martinez-Picado, E. Negredo, L. Ruiz, A. Shintani, C. Fumaz, C. Zala, P. Domingo, J. VilarÛ, J. Llibre, P. Viciana, K. Hertogs, C. Boucher, R. D'Aquila, B. Clotet, and S.S. Team Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial Ann. Intern. Med. 139 2 2003 81 89
27. J. Martinez-Quintanilla, M. Cascallo, C. Fillat, and R. Alemany Antitumor therapy based on cellular competition Hum. Gene Ther. 20 7 2009 728 738
28. J. Martinez-Quintanilla, M. Cascallo, A. Gros, C. Fillat, and R. Alemany Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy Mol. Cancer Ther. 8 11 2009 3098 3107
29. M. Marusić, Z. Bajzer, J. Freyer, and S. Vuk-Pavlović Modeling autostimulation of growth in multicellular tumor spheroids Int. J. Biomed. Comput. 29 2 1991 149 158
30. M. Marusić, Z. Bajzer, J. Freyer, and S. Vuk-Pavlović Analysis of growth of multicellular tumour spheroids by mathematical models Cell Prolif. 27 2 1994 73 94 (Pubitemid 24053399)
31. M. Marusić, Z. Bajzer, S. Vuk-Pavlović, and J. Freyer Tumor growth in vivo and as multicellular spheroids compared by mathematical models Bull. Math. Biol. 56 4 1994 617 631
32. E. McBryde, A. Pettitt, and D. McElwain A stochastic mathematical model of methicillin resistant staphylococcus aureus transmission in an intensive care unit: predicting the impact of interventions J. Theor. Biol. 245 3 2007 470 481 (Pubitemid 46365751)
33. X. Meng, T. Nakamura, T. Okazaki, H. Inoue, A. Takahashi, S. Miyamoto, G. Sakaguchi, M. Eto, S. Naito, M. Takeda, Y. Yanagi, and K. Tani Enhanced antitumor effects of an engineered measles virus edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma Mol. Ther. 18 3 2010 544 551
34. D. Nathwani Health economic issues in the treatment of drug-resistant serious gram-positive infections J. Infect. 59 Suppl 1 2009 S40 S50
35. M. Nowak Evolutionary Dynamics: Exploring the Equations of Life 2006 Harvard University Press
36. M. Nowak, S. Bonhoeffer, G. Shaw, and R. May Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations J. Theor. Biol. 184 2 1997 203 217 (Pubitemid 27089344)
37. M. Nowak, and R. May Virus Dynamics: Mathematical Principles of Immunology and Virology 2000 Oxford University Press
38. E. Oldfield, Z. Ram, K. Culver, R. Blaese, H. DeVroom, and W. Anderson Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir Hum. Gene Ther. 4 1 1993 39 69
39. A. Perelson, A. Neumann, M. Markowitz, J. Leonard, and D. Ho HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time Science 271 5255 1996 1582 1586 (Pubitemid 26097216)
40. L. Perrin, and A. Telenti HIV treatment failure: testing for HIV resistance in clinical practice Science 280 5371 1998 1871 1873 (Pubitemid 28299381)
41. B. Preston, B. Poiesz, and L. Loeb Fidelity of HIV-1 reverse transcriptase Science 242 4882 1988 1168 1171 (Pubitemid 19007042)
42. R. Ribeiro, and S. Bonhoeffer Production of resistant HIV mutants during antiretroviral therapy Proc. Natl. Acad. Sci. U.S.A. 97 14 2000 7681 7686 (Pubitemid 30460706)
43. M. Rosenfeld, S. Vickers, D. Raben, M. Wang, L. Sampson, M. Feng, E. Jaffee, and D. Curiel Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene Ann. Surg. 225 5 1997 609 620 (Pubitemid 28079109)
44. E. Rosero, and R. Zurakowski Closed-loop minimal sampling method for determining viral-load minima during switching Proc. Am. Control Conf. 2010 460 461
45. L. Ruiz, G. Carcelain, J. Martnez-Picado, S. Frost, S. Marfil, R. Paredes, J. Romeu, E. Ferrer, K. Morales-Lopetegi, B. Autran, and B. Clotet HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection AIDS 15 9 2001 F19 F27
46. M. Saif, K. Syrigos, R. Penney, and K. Kaley Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study Anticancer Res. 30 7 2010 2905 2909
47. B. Sangro, G. Mazzolini, M. Ruiz, J. Ruiz, J. Quiroga, I. Herrero, C. Qian, A. Benito, J. Larrache, C. Olagüe, J. Boan, I. Peñuelas, B. Sádaba, and J. Prieto A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma Cancer Gene Ther. August 2010
48. P. Searle, M. Chen, L. Hu, P. Race, A. Lovering, J. Grove, C. Guise, M. Jaberipour, N. James, V. Mautner, L. Young, D. Kerr, A. Mountain, S. White, and E. Hyde Nitroreductase: a prodrug-activating enzyme for cancer gene therapy Clin. Exp. Pharmacol. Physiol. 31 11 2004 811 816 (Pubitemid 39556859)
49. R. Skurray, and N. Firth Molecular evolution of multiply-antibiotic- resistant staphylococci Ciba Found. Symp. 207 1997 167 191 (Pubitemid 127820662)
50. Y. Watanabe, T. Kojima, S. Kagawa, F. Uno, Y. Hashimoto, S. Kyo, H. Mizuguchi, N. Tanaka, H. Kawamura, D. Ichimaru, Y. Urata, and T. Fujiwara A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy Oncogene 29 8 2010 1145 1154
51. D. Wodarz, and N. Komarova Computational Biology of Cancer: Lecture Notes and Mathematical Modeling 2005 World Scientific Press
52. D. Wodarz, and N. Komarova Emergence and prevention of resistance against small molecule inhibitors Semin. Cancer Biol. 15 6 2005 506 514 (Pubitemid 41318049)
53. G. Wolkersdörfer, C. Thiede, R. Fischer, G. Ehninger, and C. Haag Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma HPB (Oxford) 9 1 2007 16 25
54. J. Wong, C. Ignacio, F. Torriani, D. Havlir, N. Fitch, and D. Richman In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues J. Virol. 71 3 1997 2059 2071 (Pubitemid 27078584)
55. L. Xiao, X. Li, N. Niu, J. Qian, G. Xie, and Y. Wang Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24 Mol. Cell. Biochem. Feb. 2010
56. T. Zhu, N. Wang, A. Carr, D. Nam, R. Moor-Jankowski, D. Cooper, and D. Ho Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission J. Virol. 70 5 1996 3098 3107 (Pubitemid 26121927)
57. R. Zurakowski, and D. Wodarz Modeling and control for in vitro combination therapy using ONYX-015 replicating adenovirus Proc. Am. Control Conf. 2006 4794 4799 (Pubitemid 46531579)
58. R. Zurakowski, and D. Wodarz Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus J. Theor. Biol. 245 1 2007 1 8 (Pubitemid 46215682)
59. R. Zurakowski, and D. Wodarz Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment Proceedings of 46th IEEE conference on decision and control 2007 5174 5179 (Pubitemid 351277961)